---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Humanistic burden and health-related quality of life. Topics: Health-related quality of life, anxiety, and depression in 78 adults and 29 children with primary FSGS and their care-partners; Quality of life and health care costs in FSGS: review of three systematic literature reviews; PROMIS health-related quality of life in 478 children and 1115 adults with primary glomerular disease; Racial and ethnic differences in health-related quality of life in glomerular disease; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Health-related quality of life, anxiety, and depression in 78 adults and 29 children with primary FSGS and their care-partners

> “This study cross-sectionally surveyed patients with primary focal segmental glomerulosclerosis (FSGS) and their caregivers/care-partners, in terms of physical and mental health-related quality of life (HRQoL) and work productivity.”
> “78 adults and 29 children/adolescents with FSGS, with their care-partners/caregivers, were included. The median ages of adults and children/adolescents with FSGS were 44.5 and 12.0 years, respectively; 74.4% and 58.6% were female. Mean physical and mental SF-12 scores for adult patients were 41.9 (SD: 12.1) and 44.8 (10.2), respectively.”
> “Both SF-12 components for adult patients, the SF-12 mental component for care-partners, and all PedsQL item scores were worse compared to US general population estimates. Among adult patients, 28.2% reported at least moderate anxiety; 37.3% reported at least moderate depression. Compared to external controls, patients experienced significantly higher severity of anxiety (6.1 vs. 5.0) and depression (7.6 vs. 5.9; both p < 0.0001).”
> “Patients with FSGS and their care-partners experience impairments to mental/physical HRQoL and work productivity, underscoring the need for effective FSGS therapies and care-partner support.”

Source: [Szklarzewicz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12182477/)

<a id="topic-2.2.1.8.1-2"></a>

### Quality of life and health care costs in FSGS: review of three systematic literature reviews

> “This supplement explores the burden of FSGS from a clinical, humanistic, and economic perspective, informed by the results of 3 systematic literature reviews. FSGS is associated with poorer quality of life and high health care costs, and these outcomes are correlated with disease severity.”

Source: [Bensink et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42101820/)

<a id="topic-2.2.1.8.1-3"></a>

### PROMIS health-related quality of life in 478 children and 1115 adults with primary glomerular disease

> “We assessed the relationship between HRQOL and demographic and clinical variables in 478 children and 1115 adults at the time of enrollment into CureGN.”
> “Patient-reported edema consistently had the strongest and most robust association with each measured domain of HRQOL in multivariable analysis”
> “Female sex, weight (particularly obesity), and estimated glomerular filtration rate were also associated with some, but not all, domains of HRQOL. Primary diagnosis, disease duration, and exposure to immunosuppression were not associated with HRQOL after adjustment.”
> “There were substantial differences in racial distribution among the diagnoses, with black participants more likely to have FSGS and less likely to have IgAN or IgAV.”

Source: [Canetta et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6743723/)

<a id="topic-2.2.1.8.1-4"></a>

### Racial and ethnic differences in health-related quality of life in glomerular disease

> “Black adults missed work or school most frequently due to kidney disease (30 vs. 16–23% in the other 3 groups, p = 0.04), and had the worst self-reported global physical health (median score 44.1 vs. 48.0–48.2, p < 0.001) and fatigue (53.8 vs. 48.5–51.1, p = 0.002), compared to other racial/ethnic groups.”
> “However, these findings were not statistically significant with adjustment for socioeconomic status and disease severity, both of which were strongly associated with HRQOL in adults.”
> “Among patients with glomerular disease enrolled in CureGN, the worse HRQOL reported by black adults was attributable to lower socioeconomic status and more severe glomerular disease.”

Source: [Krissberg et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8553235/)

<a id="topic-2.2.1.8.1-5"></a>

### Health-related quality of life and outcomes in 3837 adults with CKD

> “Data from 3837 adult participants with mild to severe CKD enrolled in the prospective observational Chronic Renal Insufficiency Cohort and Hispanic Chronic Renal Insufficiency Cohort Studies were analyzed.”
> “Younger age, women, low education, diabetes, vascular disease, congestive heart failure, obesity, and lower eGFR were associated with low baseline health–related quality of life (P<0.05).”
> “Low health–related quality of life across several subscales was independently associated with a higher risk of incident cardiovascular events and death but not associated with CKD progression.”

Source: [Porter et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4934840/)

<a id="topic-2.2.1.8.1-6"></a>

### Utility values by CKD treatment modality: meta-analysis of 190 studies

> “In total, 190 studies reporting 326 utilities from over 56,000 patients were analysed.”
> “Using time tradeoff as a referent instrument, kidney transplant recipients had a mean utility of 0.82 (95% CI: 0.74, 0.90).”
> “The researchers found that the highest average utility was for those who had renal transplantation, 0.82, followed by the pre-dialysis group (0.80), dialysis patients (0.71), and, finally, patients receiving conservative care (0.62).”
> “For patients with late-stage CKD, treatment with dialysis is associated with a significant decrement in quality of life compared to treatment with kidney transplantation.”

Source: [Wyld et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3439392/)

<a id="topic-2.2.1.8.1-7"></a>

### Quality of life of caregivers of adults receiving maintenance dialysis: systematic review of 61 studies

> “61 studies were identified that included 5,367 caregivers from 21 countries and assessed the impact on caregivers using 70 different scales.”
> “Caregiver quality of life was poorer than in the general population, mostly comparable with caregivers of people with other chronic diseases, and often better than experienced by the dialysis patients cared for. Caregiver quality of life was comparable across dialysis modalities.”

Source: [Gilbertson et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30454885/)

<a id="topic-2.2.1.8.1-8"></a>

### Patient-reported concern and worry after APOL1 genotyping in 200 Black adults

> “Among 200 participants enrolled with completed 3-month follow-up as of January 2025, 17.5% (35/200) carried an APOL1 high-risk genotype (2 RRVs). At baseline, concern about kidney conditions was common: 39% reported being extremely concerned, 34% very concerned, 12% somewhat concerned, 10% a little concerned, and 6% not concerned at all.”
> “APOL1 high-risk genotypes were more common in those with an increase, compared to a decrease, in kidney concern at follow-up (29% vs 11%; P = 0.02). Worry related to having an APOL1 high-risk genotype declined over time, from 14% at baseline to 8% at 3 months.”
> “Even among healthy individuals, such as living kidney donor candidates, APOL1 testing may evoke psychological distress and fear of kidney failure (7).”

Source: [Elsurer Afsar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13438459/)

<a id="topic-2.2.1.8.1-9"></a>

### Attitudes of African American living kidney donors toward APOL1 genetic testing

> “Twenty-three donors participated in semi-structured interviews. Most (96%) reported that transplant centers should routinely offer APOL1 genetic testing to all AA potential donors.”
> “Participants believed that potential donors would experience psychological distress from learning they have two gene variants and could harm their recipients.”

Source: [Gordon et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6252162/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
